Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

<p>CONSORT Diagram</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Aurelius Omlin (14971513) (author)
Rannpháirtithe:	Richard Cathomas (14971516) (author), Gunhild von Amsberg (14971519) (author), Christoph Reuter (14971522) (author), Susan Feyerabend (14971525) (author), Wolfgang Loidl (14971528) (author), Martin Boegemann (14971531) (author), Anja Lorch (14971534) (author), Axel Heidenreich (14971537) (author), Igor Tsaur (14971540) (author), Julian Larcher-Senn (14971543) (author), Stefan A.J. Buck (14971546) (author), Ron H.J. Mathijssen (14971549) (author), Ulrich Jaehde (14971552) (author), Silke Gillessen (14971555) (author), Markus Joerger (14971558) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Chemotherapy Clinical-Stage Research Computational Methods Algorithms Genitourinary Cancers Prostate cancer Pharmacology Pharmacokinetics and pharmacodynamics
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
de réir: Aurelius Omlin (14971513)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
de réir: Evan C. Chen (15054014)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
de réir: Evan C. Chen (15054014)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
de réir: Evan C. Chen (15054014)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
de réir: Evan C. Chen (15054014)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
de réir: Evan C. Chen (15054014)
Foilsithe / Cruthaithe: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
de réir: Evan C. Chen (15054014)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Data Sheet 1_Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.docx
de réir: Yajie He (20323682)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
de réir: Yan Zhou (15053225)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
de réir: Chong Kin Liam (15331321)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
de réir: Zev A. Wainberg (15047031)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
de réir: Elizabeth R. Tucker (15053624)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
de réir: Elizabeth R. Tucker (15053624)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
de réir: Elizabeth R. Tucker (15053624)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
de réir: Elizabeth R. Tucker (15053624)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
de réir: Elizabeth R. Tucker (15053624)
Foilsithe / Cruthaithe: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
de réir: Elizabeth R. Tucker (15053624)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
de réir: Michelle L. Mierzwa (14963463)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
de réir: Alyssa C. Flint (16676029)
Foilsithe / Cruthaithe: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
de réir: Alyssa C. Flint (16676029)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
de réir: Gregory L. Beatty (15087193)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
de réir: Gregory L. Beatty (15087193)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
de réir: Zachary Quinn (15052893)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
de réir: Fabrice Barlesi (15045504)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jcbne0n1djulqdaq3gl5a135nf